Unmet Needs in Spondyloarthritis: Pathogenesis, Clinical Trial Design, and Nonpharmacologic Therapy
- 24 October 2024
- journal article
- research article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 51 (12) , 1254-1258
Abstract
A program focused on pathogenesis, clinical trial design, and nonpharmacologic mind-body therapy for spondyloarthritis (SpA) was presented at the Spondylitis Association of America Unmet Needs Conference IV. SpA pathogenesis is incompletely understood but involves a complex set of drivers, including genetics, biomechanical stress, and microbial factors. Affected tissues may include axial and peripheral joints, entheses, skin, uvea, and intestines. The specific role of key cytokines like interleukin (IL)-23, IL-17, and tumor necrosis factor in the phases of this inflammatory process remains unclear. New insights into pathogenesis will continue to generate targets for novel therapeutics. How to optimally evaluate those therapeutics in clinical trials, and for the various manifestations of SpA, remains less clear. Future trials need better generalizability, robust subgroup analyses to assess differential responses for distinct disease manifestations, a focus on comparative efficacy, and outcomes relevant to the clinician and the patient. Additionally, study designs need to leverage available technology to facilitate subject participation in trials. In view of the interplay between biologic, physical, and psychological aspects of disease, there is increasing attention to nonpharmacologic agents, with the aim of maximizing long-term health-related quality of life through the control of symptoms and inflammation. Recent studies provide encouraging evidence that mind-body interventions such as tai chi, qigong, yoga, and meditation have benefits for patients with SpA, particularly those with pain. The advances in our understanding of pathogenesis, novel therapeutics, and nonpharmacologic interventions have revolutionized the management of SpA, but numerous questions around optimal management remain.Keywords
This publication has 15 references indexed in Scilit:
- Autoimmunity-associated T cell receptors recognize HLA-B*27-bound peptidesNature, 2022
- The top 10 research priorities in psoriatic arthritis: a James Lind Alliance Priority Setting PartnershipRheumatology, 2022
- Macrophage migration inhibitory factor drives pathology in a mouse model of spondyloarthritis and is associated with human diseaseScience Translational Medicine, 2021
- What influences patients’ opinion of remission and low disease activity in psoriatic arthritis? Principal component analysis of an international studyRheumatology, 2021
- GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritisAnnals of the Rheumatic Diseases, 2020
- Evidence that tissue resident human enthesis γδT-cells can produce IL-17A independently of IL-23R transcript expressionAnnals of the Rheumatic Diseases, 2019
- What constitutes the fat signal detected by MRI in the spine of patients with ankylosing spondylitis? A prospective study based on biopsies obtained during planned spinal osteotomy to correct hyperkyphosis or spinal stenosisAnnals of the Rheumatic Diseases, 2019
- Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countriesAnnals of the Rheumatic Diseases, 2019
- Application of composite disease activity scores in psoriatic arthritis to the PRESTA data setAnnals of the Rheumatic Diseases, 2012
- Adalimumab for long‐term treatment of psoriatic arthritis: Forty‐eight week data from the adalimumab effectiveness in psoriatic arthritis trialArthritis & Rheumatism, 2007